NEJ026: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations

被引：5
|
作者：
Maemondo, M. [1 ]
Fukuhara, T. [1 ]
Sugawara, S. [2 ]
Takiguchi, Y. [3 ]
Inoue, A. [4 ]
Oizumi, S. [5 ]
Ishii, Y. [6 ]
Yoshizawa, H. [7 ]
Isobe, T. [8 ]
Gemma, A. [9 ]
Morita, S. [10 ]
Hagiwara, K. [11 ]
Kobayashi, K. [12 ]
Nukiwa, T. [13 ]
机构：
[1] Miyagi Canc Ctr, Resp Med, Natori, Miyagi, Japan
[2] Sendai Kousei Hosp, Pulm Med, Sendai, Miyagi, Japan
[3] Chiba Univ, Sch Med, Dept Med Oncol, Chiba, Japan
[4] Tohoku Univ Hosp, Palliat Med, Sendai, Miyagi, Japan
[5] Hokkaido Canc Ctr, Resp Med, Sapporo, Hokkaido, Japan
[6] Dokkyo Med Univ, Pulm Med & Clin Immunol, Mibu, Tochigi, Japan
[7] Niigata Med Ctr Hosp, Resp Med, Niigata, Japan
[8] Shimane Univ, Fac Med, Med Oncol & Resp Med, Matsue, Shimane, Japan
[9] Main Hosp, Nippon Med Sch, Resp Med, Tokyo, Japan
[10] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[11] Jichi Med Univ, Pulm Med, Shimotsuke, Tochigi, Japan
[12] Saitama Med Univ, Int Med Ctr, Resp Med, Hidaka, Japan
[13] Japan AntiTB Assoc, Resp Med, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw383.86
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1286TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II study of fruquintinib plus gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations
    Lu, S.
    Zhou, J.
    Niu, X.
    Chen, Y.
    Su, W.
    ANNALS OF ONCOLOGY, 2019, 30
  • [22] Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
    Kenmotsu, Hirotsugu
    Wakuda, Kazushige
    Mori, Keita
    Kato, Terufumi
    Sugawara, Shunichi
    Kirita, Keisuke
    Yoneshima, Yasuto
    Azuma, Koichi
    Nishino, Kazumi
    Teraoka, Shunsuke
    Shukuya, Takehito
    Masuda, Ken
    Hayashi, Hidetoshi
    Toyozawa, Ryo
    Miura, Satoru
    Fujimoto, Daichi
    Nakagawa, Kazuhiko
    Yamamoto, Nobuyuki
    Takahashi, Toshiaki
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : 1098 - 1108
  • [23] NEJ043: A phase 2 study of atezolizumab (atezo) plus bevacizumab (bev) plus carboplatin (carbo) plus paclitaxel (pac; ABCP) for previously treated patients with NSCLC harboring EGFR mutations (EGFRm).
    Furuya, Naoki
    Watanabe, Satoshi
    Nakamura, Atsushi
    Shiihara, Jun
    Nakachi, Ichiro
    Tanaka, Hisashi
    Nakao, Mika
    Minato, Koichi
    Seike, Masahiro
    Sasaki, Shinichi
    Kisohara, Akira
    Takeuchi, Susumu
    Honda, Ryoichi
    Takamura, Kei
    Kagamu, Hiroshi
    Yoshimura, Kenichi
    Kikuchi, Toshiaki
    Kobayashi, Kunihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)
    Stinchcombe, T. E.
    Janne, P. A.
    Wang, X.
    Bertino, E. M.
    Weiss, J. M.
    Bazhenova, L.
    Gu, L.
    Lau, C. J.
    Paweletz, C. P.
    Jaslowski, A. J.
    Gerstner, G. J.
    Baggstrom, M. Q.
    Graziano, S. L.
    Beardenlii, J.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2018, 29 : 522 - 522
  • [25] A Phase I Trial of Afatinib and Bevacizumab in Untreated Patients with Advanced NSCLC Harboring EGFR-Mutations: OLCSG1404
    Kuyama, S.
    Kudo, K.
    Tamura, T.
    Nishi, T.
    Harada, D.
    Bessho, A.
    Fujimoto, N.
    Minami, D.
    Aoe, K.
    Ninomiya, T.
    Kiura, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1964 - S1964
  • [26] Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer
    Philip, Philip A.
    Mahoney, Michelle R.
    Holen, Kyle D.
    Northfelt, Donald W.
    Pitot, Henry C.
    Picus, Joel
    Flynn, Patrick J.
    Erlichman, Charles
    CANCER, 2012, 118 (09) : 2424 - 2430
  • [27] CUSTOMIZING ERLOTINIB IN METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (P) HARBORING EGFR MUTATIONS
    Sirera, R.
    Catot, S.
    Gonzalez-Larriba, J. L.
    Bover, I.
    Alonso, G.
    Valdivia, J.
    Ibeas, R.
    Lianes, P.
    Martinez del Prado, P.
    Rosell, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 90 - 90
  • [28] Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.
    Azuma, Koichi
    Yoshioka, Hiroshige
    Yamamoto, Nobuyuki
    Takahashi, Toshiaki
    Nishio, Makoto
    Katakami, Nobuyuki
    Ahn, Myung-Ju
    Hirashima, Tomonori
    Maemondo, Makoto
    Kim, Sang-We
    Noshiro, Masayoshi
    Akinaga, Shiro
    Park, Keunchil
    Tsai, Chun-Ming
    Tamura, Tomohide
    Mitsudomi, Tetsuya
    Nakagawa, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] A Phase II Study of Afatinib Treatment for Elderly Patients with Previously Untreated Advanced NSCLC Harboring EGFR Mutations
    Suzuki, K.
    Imai, H.
    Kaira, K.
    Anzai, M.
    Tsuda, T.
    Ishizuka, T.
    Kuwako, T.
    Naruse, I.
    Nemoto, K.
    Uchino, J.
    Morozumi, N.
    Ishihara, S.
    Minato, K.
    Hisada, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S498 - S498
  • [30] Bevacizumab plus erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial
    Piccirillo, M. C.
    Bonanno, L.
    Garassino, M. C. C.
    Dazzi, C.
    Cavanna, L.
    Esposito, G.
    Burgio, M. A.
    Rosetti, F.
    Rizzato, S.
    Arenare, L.
    Gargiulo, P.
    Di Liello, R.
    De Marinis, F.
    Crino, L.
    Morgillo, F.
    Ciardiello, F.
    Normanno, N.
    Gallo, C.
    Gridelli, C.
    Morabito, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S950 - S950
12345